Publication: Follow-up of patients with epilepsy harboring antiglycine receptor antibodies
Program
KU-Authors
KU Authors
Co-Authors
Ekizoğlu, Esme
Baykan, Betül
Sezgin, Mine
Erdağ, Ece
Gündoğdu-Ünverengil, Gökçen
Tektürk, Pınar
Yılmaz, Ebru
Bebek, Nerses
Tüzün, Erdem
Publication Date
Language
Type
Embargo Status
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Objective: The long-term follow-up of patients with epilepsy harboring autoantibodies against the glycine receptor (also glycine receptor antibodies or GlyR-Ab) is not well-known. Our aim was to investigate the 5-year prognosis and treatment response of patients with epilepsy who were seropositive for GlyR-Ab. Methods: Clinical features; electroencephalogram (EEG), neuroradiological, and neuropathological findings; and treatment responses of patients with epilepsy with GlyR-Ab seropositivity were investigated. Results: Thirteen (5.46%) of 238 patients with epilepsy were GlyR-Ab positive: focal epilepsy of unknown cause (FEoUC) was diagnosed in four (7.27%) out of 55 patients, mesial temporal lobe epilepsy with hippocampal sderosis (MTLE-HS) in five (4.5%) out of 111 patients, epileptic encephalopathy (EE) in two (4%) out of 50 patients, and status epilepticus (SE) in two (9.09%) out of 22 patients. None of the patients developed any other neurological symptoms or cancer during the 5-year follow-up. Seven of them had seizures that were resistant to antiepileptic drug (AED). Immunotherapy was used in two patients (with FEoUC and EE) improving seizure control. Three patients with MTLE-HS benefited from epilepsy surgery, and another patient with EE showed spontaneous remission. Conclusion: Glycine receptor antibodies are detected in a wide spectrum of epileptic disorders with undear pathogenic significance. Two GlyR-Ab seroposilive patients with AED-resistant epilepsy treated with intravenous immunoglobulin (Mg) showed dear benefit from immunotherapy. Future studies will be valuable in determining the role of screening patients with drug-resistant epilepsy for GlyR-Ab in order to identify patients who may benefit or respond to immunotherapy.
Source
Publisher
Elsevier
Subject
Psychology, Clinical neuropsychology, Psychiatry
Citation
Has Part
Source
Epilepsy and Behavior
Book Series Title
Edition
DOI
10.1016/j.yebeh.2018.09.034